Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation
A decade since immune checkpoint inhibitors made a stride in the clinical landscape of oncology, there has been a substantial focus on understanding the response heterogeneity following these therapies. Insights gained from clinical data identified the…